Medicine
Brevital Sodium 500 mg powder for injection
Brevital Sodium 500 mg powder for injection is a prescription medicine containing Methohexital for intramuscular, intravenous, rectal use, marketed by Par Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store between 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Methohexital
- Brand
- Brevital Sodium
- Strength
- 500 mg
- Dosage form
- Powder for injection
- Route
- Intramuscular, intravenous, rectal
- Packs
- 1 vial
- Marketing authorisation holder
- Par Health
- Manufacturer
- Par Health
- Origin register
- US FDA, United States
- Storage
- Store between 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Schedule CIV
- ATC code
- N01AF01 Methohexital
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 November 2007
- Identifiers
- RxCUI 1244233, 1244638DailyMed set ID eccd8340-ead3-4363-8902-0c19d33aa2acNDC 42023-105Application NDA011559
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial | 42023-105-01 | Par Health | 1 November 2007 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 27 June 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Methohexital
Clinical summary
Methohexital is a barbiturate. It is available as injection and powder for injection for intravenous, intramuscular and rectal use. MedsAcross supplies Methohexital for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MethohexitalFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Brevital Sodium prescribing information (Par Health) · U.S. National Library of Medicine, DailyMed
Need Brevital Sodium 500 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.